Business Wire | Jan 4, 2021 06:30AM EST

BiomX to Present at Upcoming January Investor Conferences

Jan. 04, 2021

NESS ZIONA, Israel--(BUSINESS WIRE)--Jan. 04, 2021--BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that Jonathan Solomon, Chief Executive Officer, will participate in the following upcoming investor conferences.

Event: H.C. Wainwright BioConnect ConferenceDates: January 11-14, 2021 Time: Playback available 6 a.m. EST January 11 Webcast link: BiomX - HCW BioConnect Conference Playback The webcast will also be available in the Events section of the BiomX website at www.biomx.com.

Event: Oppenheimer Virtual Banking MeetingDates: January 11-14, 2021 1x1 meetings only

About BiomX

BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as inflammatory bowel disease, primary sclerosing cholangitis, cystic fibrosis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

Additional information is available at www.biomx.com, the content of which does not form a part of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005096/en/

CONTACT: Noel Kurdi, BiomX VP Investor Relations and Strategy (646) 241-4400 noelk@biomx.com

CONTACT: Media contact: Rich Allan, Solebury Trout (646) 378-2958 rallan@soleburytrout.com